본문 바로가기
KERD
논문KCI 등재

A New Paradigm Shift in Gastroparesis Management

Rerknimitr Rungsun|Mekaroonkamol Parit|Tiankanon Kasenee
거트앤리버 소화기연관학회협의회|2022.11|Gut and Liver|제16권 제6호|pp. 825-839|DOI 10.5009/gnl210309

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

TreatmentOutcomesGastroparesisPyloromyotomy

초록

Gastroparesis, once regarded as a rare disease, is difficult to diagnose and challenging to treat; there were many breakthrough advances in the 2010s, shifting the paradigm of the understanding of this complex entity and its management. Similar to diabetes, its increasing prevalence reflects increased accessibility to diagnostic modalities and suggests that gastroparesis was underacknowledged in the past. Major developments in the three main aspects of the disease include the discovery of smooth muscle cells, interstitial cells of Cajal, PDGFRα+ cells syncytium, rather than interstitial cells of Cajal alone, as the main gastric pacemaker unit; the development of validated point-of-care diagnostic modalities such as a wireless motility capsule, the carbon 13-labeled breath test, and impedance planimetry; and the introduction of novel minimally invasive therapeutic options such as newer pharmacologic agents and gastric peroral endoscopic pyloromyotomy. All aspects of these advances will be discussed further in this review.

Abstract

Gastroparesis, once regarded as a rare disease, is difficult to diagnose and challenging to treat; there were many breakthrough advances in the 2010s, shifting the paradigm of the understanding of this complex entity and its management. Similar to diabetes, its increasing prevalence reflects increased accessibility to diagnostic modalities and suggests that gastroparesis was underacknowledged in the past. Major developments in the three main aspects of the disease include the discovery of smooth muscle cells, interstitial cells of Cajal, PDGFRα+ cells syncytium, rather than interstitial cells of Cajal alone, as the main gastric pacemaker unit; the development of validated point-of-care diagnostic modalities such as a wireless motility capsule, the carbon 13-labeled breath test, and impedance planimetry; and the introduction of novel minimally invasive therapeutic options such as newer pharmacologic agents and gastric peroral endoscopic pyloromyotomy. All aspects of these advances will be discussed further in this review.

참고문헌 (138)

  1. Wang YR, "Gastroparesis-related hospitalizations in the United States : trends, characteristics, and outcomes, 1995-2004", Am J Gastroenterol, 103, pp.313~322 (2008)
  2. Saleem S, "In-hospital mortality in gastroparesis population and its predictors : a United States-based population study", JGH Open, 5, pp.350~355 (2021)
  3. Lacy BE, "Gastroparesis : quality of life and health care utilization", J Clin Gastroenterol, 52, pp.20~24 (2018)
  4. Jung HK, "The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006", Gastroenterology, 136, pp.1225~1233 (2009)
  5. Christensen J, "Manometric diagnosis of gastrointestinal motility disorders", Mayo Clin Proc, 61, pp.998~999 (1986)
  6. Kelly KA, "Gastric emptying of liquids and solids : roles of proximal and distal stomach", Am J Physiol, 239, pp.G71~G76 (1980)
  7. Williams PA, "Long-term effects of gastric stimulation on gastric electrical physiology", J Gastrointest Surg, 17, pp.50~56 (2013)
  8. Camilleri M, "Clinical guideline:management of gastroparesis", Am J Gastroenterol, 108, pp.18~37 (2013)
  9. Grover M, "Gastroparesis : a turning point in understanding and treatment", Gut, 68, pp.2238~2250 (2019)
  10. Vosoughi K, "Gastric per-oral endoscopic myotomy(G-POEM)for refractory gastroparesis : results from an international prospective trial", Gut, 71, pp.25~33 (2022)
  11. Enrique Rey, "Prevalence of Hidden Gastroparesis in the Community: The Gastroparesis “Iceberg”", Journal of Neurogastroenterology and Motility (JNM), 18(1), pp.34~42 (2012), 대한소화기 기능성질환∙운동학회
  12. Jones KL, "Predictors of delayed gastric emptying in diabetes", Diabetes Care, 24, pp.1264~1269 (2001)
  13. Choung RS, "Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population", Am J Gastroenterol, 107, pp.82~88 (2012)
  14. Jones KL, "A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus", Am J Med, 113, pp.449~455 (2002)
  15. Wald A, "Gastrointestinal transit : the effect of the menstrual cycle", Gastroenterology, 80, pp.1497~1500 (1981)
  16. Yu D, "The burdens, concerns, and quality of life of patients with gastroparesis", Dig Dis Sci, 62, pp.879~893 (2017)
  17. Moshiree B, "Epidemiology and pathophysiology of gastroparesis", Gastrointest Endosc Clin N Am, 29, pp.1~14 (2019)
  18. Vijayvargiya P, "Association between delayed gastric emptying and upper gastrointestinal symptoms : a systematic review and meta-analysis", Gut, 68, pp.804~813 (2019)
  19. Chedid V, "Characterization of upper gastrointestinal symptoms, gastric motor functions, and associations in patients with diabetes at a referral center", Am J Gastroenterol, 114, pp.143~154 (2019)
  20. Carbone F, "Relationship between gastric emptying rate and simultaneously assessed symptoms in functional dyspepsia", Clin Gastroenterol Hepatol, 20, pp.E429~E437 (2022)
  21. Stanghellini V, "Gastroduodenal disorders", Gastroenterology, 150, pp.1380~1392 (2016)
  22. Mekaroonkamol P, "Gastric peroral endoscopic pyloromyotomy reduces symptoms, increases quality of life, and reduces health care use for patients with gastroparesis", Clin Gastroenterol Hepatol, 17, pp.82~89 (2019)
  23. Revicki DA, "Evaluating symptom outcomes in gastroparesis clinical trials : validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary(GCSI-DD)", Neurogastroenterol Motil, 24, pp.456~463 (2012)
  24. El-Serag HB, "Systemic review : the prevalence and clinical course of functional dyspepsia", Aliment Pharmacol Ther, 19, pp.643~654 (2004)
  25. Soykan I, "Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis", Dig Dis Sci, 43, pp.2398~2404 (1998)
  26. van Lelyveld N, "Lack of relationship between chronic upper abdominal symptoms and gastric function in functional dyspepsia", Dig Dis Sci, 53, pp.1223~1230 (2008)
  27. Lacy BE, "Functional dyspepsia and gastroparesis : one disease or two", Am J Gastroenterol, 107, pp.1615~1620 (2012)
  28. Revicki DA, "Gastroparesis Cardinal Symptom Index(GCSI) : development and validation of a patient reported assessment of severity of gastroparesis symptoms", Qual Life Res, 13, pp.833~844 (2004)
  29. Jehangir A, "Rome IV diagnostic questionnaire complements patient assessment of gastrointestinal symptoms for patients with gastroparesis symptoms", Dig Dis Sci, 63, pp.2231~2243 (2018)
  30. Stanghellini V, "Gastroparesis : separate entity or just a part of dyspepsia", Gut, 63, pp.1972~1978 (2014)
  31. Vanheel H, "Pathophysiological abnormalities in functional dyspepsia subgroups according to the Rome III criteria", Am J Gastroenterol, 112, pp.132~140 (2017)
  32. Faussone-Pellegrini MS, "Ultrastructural differences between diabetic and idiopathic gastroparesis", J Cell Mol Med, 16, pp.1573~1581 (2012)
  33. Grover M, "Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis", BMC Med Genomics, 11, pp.62~ (2018)
  34. Bashashati M, "Pathological findings of the antral and pyloric smooth muscle in patients with gastroparesis-like syndrome compared to gastroparesis : similarities and differences", Dig Dis Sci, 62, pp.2828~2833 (2017)
  35. Sanders KM, "Regulation of gastrointestinal smooth muscle function by interstitial cells", Physiology(Bethesda), 31, pp.316~326 (2016)
  36. Herring BP, "Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa", Neurogastroenterol Motil, 30, pp.e13230~ (2018)
  37. Grover M, "Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum", Neurogastroenterol Motil, 29, pp.e13018~ (2017)
  38. Soota K, "Immunomodulation for treatment of drug and device refractory gastroparesis", Results Immunol, 6, pp.11~14 (2016)
  39. Flanagan EP, "Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility", Neurogastroenterol Motil, 26, pp.1285~1297 (2014)
  40. Stanghellini V, "Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia", Gut, 33, pp.184~190 (1992)
  41. Gonlachanvit S, "Regional gastric emptying abnormalities in functional dyspepsia and gastro-oesophageal reflux disease", Neurogastroenterol Motil, 18, pp.894~904 (2006)
  42. Vella A, "The gastrointestinal tract as an integrator of mechanical and hormonal response to nutrient ingestion", Diabetes, 66, pp.2729~2737 (2017)
  43. Camilleri M, "Gastrointestinal hormones and regulation of gastric emptying", Curr Opin Endocrinol Diabetes Obes, 26, pp.3~10 (2019)
  44. Friedenberg FK, "Tonic and phasic pyloric activity in response to CCK-octapeptide", Dig Dis Sci, 53, pp.905~911 (2008)
  45. Beom Jin Kim, "Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment", Journal of Neurogastroenterology and Motility (JNM), 25(1), pp.27~35 (2019), 대한소화기 기능성질환∙운동학회[DOI]
  46. Schwartz MZ, "Pediatric surgery. Volume 2", pp.1021~1028 (2012), Elsevier
  47. Cogliandro RF, "Is gastroparesis a gastric disease?", Neurogastroenterol Motil, 31, pp.e13562~ (2019)
  48. Huizinga JD, "Gut peristalsis is governed by a multitude of cooperating mechanisms", Am J Physiol Gastrointest Liver Physiol, 296, pp.G1~G18 (2009)
  49. Malik Z, "Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis", Neurogastroenterol Motil, 27, pp.524~531 (2015)
  50. Snape WJ, "Evaluation of the pylorus with concurrent intraluminal pressure and EndoFLIP in patients with nausea and vomiting", Neurogastroenterol Motil, 28, pp.758~764 (2016)
  51. Blackett JW, "Risk factors and outcomes for gastroparesis after lung transplantation", Dig Dis Sci, 67, pp.2385~2394 (2022)
  52. Pasricha PJ, "White Paper AGA : gastroparesis : clinical and regulatory insights for clinical trials", Clin Gastroenterol Hepatol, 15, pp.1184~1190 (2017)
  53. Tougas G, "Assessment of gastric emptying using a low fat meal : establishment of international control values", Am J Gastroenterol, 95, pp.1456~1462 (2000)
  54. Parkman HP, "Assessment of gastric emptying and smallbowel motility : scintigraphy, breath tests, manometry, and SmartPill", Gastrointest Endosc Clin N Am, 19, pp.49~55 (2009)
  55. Szarka LA, "A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research", Clin Gastroenterol Hepatol, 6, pp.635~643 (2008)
  56. Viramontes BE, "Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying", Neurogastroenterol Motil, 13, pp.567~574 (2001)
  57. George NS, "Small intestinal bacterial overgrowth in gastroparesis", Dig Dis Sci, 59, pp.645~652 (2014)
  58. Kuo B, "Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects", Aliment Pharmacol Ther, 27, pp.186~196 (2008)
  59. Thomas A Zikos, "High Prevalence of Slow Transit Constipation in Patients With Gastroparesis", Journal of Neurogastroenterology and Motility (JNM), 25(2), pp.267~275 (2019), 대한소화기 기능성질환∙운동학회[DOI]
  60. Lee AA, "Validation of diagnostic and performance characteristics of the wireless motility capsule in patients with suspected gastroparesis", Clin Gastroenterol Hepatol, 17, pp.1770~1779 (2019)
  61. Spandorfer RM, "Gastric emptying scintigraphy before gastric per oral endoscopic myotomy : imaging may inform treatment", Gastrointest Endosc Clin N Am, 29, pp.127~137 (2019)
  62. Shanker A, "Measurement of pyloric pressures in gastroparesis: stiffcompetition from EndoFLIP™", Dig Dis Sci, 66, pp.2475~2477 (2021)
  63. Guo WJ, "Relationship between symptoms and gastric emptying of solids in functional dyspepsia", J Int Med Res, 40, pp.1725~1734 (2012)
  64. Sullivan A, "Pathophysiology, aetiology and treatment of gastroparesis", Dig Dis Sci, 65, pp.1615~1631 (2020)
  65. van den Elzen BD, "Fundic accommodation assessed by SPECT scanning : comparison with the gastric barostat", Gut, 52, pp.1548~1554 (2003)
  66. Orthey P, "Intragastric meal distribution during gastric emptying scintigraphy for assessment of fundic accommodation : correlation with symptoms of gastroparesis", J Nucl Med, 59, pp.691~697 (2018)
  67. Parkman HP, "American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis", Gastroenterology, 127, pp.1592~1622 (2004)
  68. Olausson EA, "A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis : a randomized controlled trial", Am J Gastroenterol, 109, pp.375~385 (2014)
  69. Navas CM, "Symptomatic management of gastroparesis", Gastrointest Endosc Clin N Am, 29, pp.55~70 (2019)
  70. Rao AS, "Review article : metoclopramide and tardive dyskinesia", Aliment Pharmacol Ther, 31, pp.11~19 (2010)
  71. Schey R, "Domperidone to treat symptoms of gastroparesis : benefits and side effects from a large single-center cohort", Dig Dis Sci, 61, pp.3545~3551 (2016)
  72. Patterson D, "A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis", Am J Gastroenterol, 94, pp.1230~1234 (1999)
  73. Singh H, "Efficacy and tolerability of levosulipride, domperidone and metoclopramide in patients with non-ulcer functional dyspepsia: a comparative analysis", J Clin Diagn Res, pp.FC9~FC12 (2015)
  74. Tonini M, "Review article : clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics", Aliment Pharmacol Ther, 19, pp.379~390 (2004)
  75. Carbone F, "Prucalopride in gastroparesis : a randomized placebo-controlled crossover study", Am J Gastroenterol, 114, pp.1265~1274 (2019)
  76. Sharma A, "Gastroparesis in the 2020s : new treatments, new paradigms", Curr Gastroenterol Rep, 22, pp.23~ (2020)
  77. Ikeo K, "Acotiamide improves stressinduced impaired gastric accommodation", Neurogastroenterol Motil, 29, pp.e12991~ (2017)
  78. Masuy I, "Acotiamide affects antral motility, but has no effect on fundic motility, gastric emptying or symptom perception in healthy participants", Neurogastroenterol Motil, 31, pp.e13540~ (2019)
  79. Tack J, "Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia", Clin Gastroenterol Hepatol, 10, pp.1239~1245 (2012)
  80. Jacob DA, "A randomized, placebo-controlled trial of the effects of aprepitant, an NK1 receptor antagonist, on gastric motor functions and satiation in healthy volunteers : 1210", Am J Gastroenterol, 112, pp.S663~S664 (2017)
  81. Carlin JL, "Tradipitant complete responder analysis in gastroparesis patients", Am J Gastroenterol, 114, pp.S691~S691 (2019)
  82. Lembo A, "Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis", Gastroenterology, 151, pp.87~96 (2016)
  83. Camilleri M, "Overall safety of relamorelin in adults with diabetic gastroparesis : analysis of phase 2a and 2b trial data", Aliment Pharmacol Ther, 51, pp.1139~1148 (2020)
  84. Acosta A, "Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial", Clin Gastroenterol Hepatol, 13, pp.2312~2319 (2015)
  85. Parkinson Study Group, "A randomized trial of relamorelin for constipation in Parkinson’s disease (MOVE-PD): trial results and lessons learned", Parkinsonism Relat Disord, 37, pp.101~105 (2017)
  86. Venkatesan T, "Role of chronic cannabis use : cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome", Neurogastroenterol Motil, 31(Suppl 2), pp.e13606~ (2019)
  87. McCarty TR, "Trends and socioeconomic health outcomes of cannabis use among patients with gastroparesis : a United States nationwide inpatient sample analysis", J Clin Gastroenterol, 56, pp.324~330 (2022)
  88. Jehangir A, "Cannabinoid use in patients with gastroparesis and related disorders : prevalence and benefit", Am J Gastroenterol, 114, pp.945~953 (2019)
  89. Parkman HP, "Effect of nortriptyline on symptoms of idiopathic gastroparesis : the NORIG randomized clinical trial", JAMA, 310, pp.2640~2649 (2013)
  90. Talley NJ, "Effect of amitriptyline and escitalopram on functional dyspepsia : a multicenter, randomized controlled study", Gastroenterology, 149, pp.340~349 (2015)
  91. Malamood M, "Mirtazapine for symptom control in refractory gastroparesis", Drug Des Devel Ther, 11, pp.1035~1041 (2017)
  92. Roldan CJ, "Randomized controlled double-blind trial comparing haloperidol combined with conventional therapy to conventional therapy alone in patients with symptomatic gastroparesis", Acad Emerg Med, 24, pp.1307~1314 (2017)
  93. Mansi C, "Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis", Aliment Pharmacol Ther, 14, pp.561~569 (2000)
  94. Deena Midani, "Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study", Journal of Neurogastroenterology and Motility (JNM), 22(4), pp.650~655 (2016), 대한소화기 기능성질환∙운동학회[DOI]
  95. Huestis MA, "Human cannabinoid pharmacokinetics", Chem Biodivers, 4, pp.1770~1804 (2007)
  96. Dacha S, "Outcomes and quality-of-life assessment after gastric per-oral endoscopic pyloromyotomy(with video)", Gastrointest Endosc, 86, pp.282~289 (2017)
  97. Shlomovitz E, "Early human experience with per-oral endoscopic pyloromyotomy(POP)", Surg Endosc, 29, pp.543~551 (2015)
  98. Moraveji S, "Depleted interstitial cells of Cajal and fibrosis in the pylorus : novel features of gastroparesis", Neurogastroenterol Motil, 28, pp.1048~1054 (2016)
  99. Davis BR, "The long-term efficacy and safety of pyloroplasty combined with gastric electrical stimulation therapy in gastroparesis", J Gastrointest Surg, 21, pp.222~227 (2017)
  100. Sarosiek I, "The addition of pyloroplasty as a new surgical approach to enhance effectiveness of gastric electrical stimulation therapy in patients with gastroparesis", Neurogastroenterol Motil, 25, pp.134~ (2013)[DOI]
  101. Hibbard ML, "Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement", J Gastrointest Surg, 15, pp.1513~1519 (2011)
  102. Arts J, "Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients", Aliment Pharmacol Ther, 24, pp.661~667 (2006)
  103. Khashab MA, "Refractory gastroparesis can be successfully managed with endoscopic transpyloric stent placement and fixation(with video)", Gastrointest Endosc, 82, pp.1106~1109 (2015)
  104. Arts J, "Clinical trial : a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis", Aliment Pharmacol Ther, 26, pp.1251~1258 (2007)
  105. Friedenberg FK, "Botulinum toxin A for the treatment of delayed gastric emptying", Am J Gastroenterol, 103, pp.416~423 (2008)
  106. Khashab MA, "Gastric per-oral endoscopic myotomy for refractory gastroparesis : results from the first multicenter study on endoscopic pyloromyotomy(with video)", Gastrointest Endosc, 85, pp.123~128 (2017)
  107. Khashab MA, "Gastric peroral endoscopic myotomy for refractory gastroparesis : first human endoscopic pyloromyotomy(with video)", Gastrointest Endosc, 78, pp.764~768 (2013)
  108. Mekaroonkamol P, "Outcomes of per oral endoscopic pyloromyotomy in gastroparesis worldwide", World J Gastroenterol, 25, pp.909~922 (2019)
  109. Mekaroonkamol P, "Outcomes of per oral endoscopic pyloromyotomy in the United States", Gastrointest Endosc Clin N Am, 29, pp.151~160 (2019)
  110. Abdelfatah MM, "Long-term outcome of gastric per-oral endoscopic pyloromyotomy in treatment of gastroparesis", Clin Gastroenterol Hepatol, 19, pp.816~824 (2021)
  111. Jacques J, "Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis : prospective trial with assessment of pyloric function", Endoscopy, 51, pp.40~49 (2019)
  112. Allemang MT, "How I do it : per-oral pyloromyotomy(POP)", J Gastrointest Surg, 21, pp.1963~1968 (2017)
  113. Malik Z, "Gastric per oral endoscopic myotomy(G-POEM)for the treatment of refractory gastroparesis : early experience", Dig Dis Sci, 63, pp.2405~2412 (2018)
  114. Rodriguez JH, "Per oral endoscopic pyloromyotomy for refractory gastroparesis : initial results from a single institution", Surg Endosc, 31, pp.5381~5388 (2017)
  115. Hyunsoo Chung, "Gastric Peroral Endoscopic Myotomy", Clinical Endoscopy, 51(1), pp.28~32 (2018), 대한소화기내시경학회
  116. Reja M, "Gastric peroral endoscopic myotomy : a specific learning curve", J Clin Gastroenterol, 56, pp.339~342 (2022)
  117. Mohan BP, "Clinical efficacy of gastric per-oral endoscopic myotomy(G-POEM)in the treatment of refractory gastroparesis and predictors of outcomes : a systematic review and meta-analysis using surgical pyloroplasty as a comparator group", Surg Endosc, 34, pp.3352~3367 (2020)
  118. Spadaccini M, "Gastric peroral endoscopic pyloromyotomy for refractory gastroparesis : a systematic review of early outcomes with pooled analysis", Gastrointest Endosc, 91, pp.746~752 (2020)
  119. Aghaie Meybodi M, "Efficacy and feasibility of G-POEM in management of patients with refractory gastroparesis : a systematic review and metaanalysis", Endosc Int Open, 7, pp.E322~E329 (2019)
  120. Zhang WG, "Longterm outcomes of peroral endoscopic myotomy in achalasia patients with a minimum follow-up of 7 years", Chin Med J(Engl), 133, pp.996~998 (2020)
  121. Podboy AJ, "Long-term outcomes of per-oral endoscopic myotomy compared to laparoscopic Heller myotomy for achalasia : a single-center experience", Surg Endosc, 35, pp.792~801 (2021)
  122. Kahaleh M, "741 Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis : a multi-centered international experience", Gastrointest Endosc, 85, pp.AB105~AB106 (2017)
  123. Hernández-Mondragón OV, "Gastric per-oral endoscopic pyloromyotomy in the treatment of refractory gastroparesis: report on the first case performed in Mexico", Rev Gastroenterol Mex(Engl Ed), 83, pp.459~461 (2018)
  124. Mekaroonkamol P, "Gastric peroral endoscopic pyloromyotomy(G-POEM)as a salvage therapy for refractory gastroparesis : a case series of different subtypes", Neurogastroenterol Motil, 28, pp.1272~1277 (2016)
  125. Watts LS, "Impact of gastric per-oral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients", Neurogastroenterol Motil, 32, pp.e13892~ (2020)
  126. Jehangir A, "EndoFLIP and pyloric dilation for gastroparesis symptoms refractory to pyloromyotomy", pyloroplasty, 2021, pp.66, 2682~2690
  127. Murray FR, "Pyloric dilation with the esophageal functional lumen imaging probe in gastroparesis improves gastric emptying, pyloric distensibility, and symptoms", Gastrointest Endosc, 94, pp.486~494 (2021)
  128. Attaar M, "Significant changes in impedance planimetry(EndoFLIP™)measurements after peroral pyloromyotomy for delayed gastric emptying", Surg Endosc, 36, pp.1536~1543 (2022)
  129. Gregor L, "Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis : a prospective single-center experience with mid-term followup(with video)", Gastrointest Endosc, 94, pp.35~44 (2021)
  130. Fathalizadeh A, "Real-time intraoperative functioning lumen imaging probe during endoscopic per-oral pyloromyotomy(pop)", Surg Endosc, 36, pp.745~752 (2022)
  131. Edy E Soffer, "Gastric Electrical Stimulation for Gastroparesis", Journal of Neurogastroenterology and Motility (JNM), 18(2), pp.131~137 (2012), 대한소화기 기능성질환∙운동학회[DOI]
  132. Bielefeldt K, "Adverse events of gastric electrical stimulators recorded in the Manufacturer and User Device Experience(MAUDE)Registry", Auton Neurosci, 202, pp.40~44 (2017)
  133. McCallum RW, "Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study", Clin Gastroenterol Hepatol, 8, pp.947~954 (2010)
  134. Levinthal DJ, "Systematic review and meta-analysis : gastric electrical stimulation for gastroparesis", Auton Neurosci, 202, pp.45~55 (2017)
  135. Shen S, "Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis : a propensity score-matched analysis of long term outcomes", Endoscopy, 52, pp.349~358 (2020)
  136. Zoll B, "Outcomes of surgical intervention for refractory gastroparesis : a systematic review", J Surg Res, 231, pp.263~269 (2018)
  137. McCarty TR, "Endoscopic treatment of gastroparesis", World J Gastroenterol, 21, pp.6842~6849 (2015)
  138. Landreneau JP, "Laparoscopic pyloroplasty versus endoscopic per-oral pyloromyotomy for the treatment of gastroparesis", Surg Endosc, 33, pp.773~781 (2019)

관련 논문AI추천

Gastroparesis Updates on Pathogenesis and ManagementNanlong Liu, Thomas Abell거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제5호Gastroparesis: Current Concepts and ManagementJan Tack, Tatsuhiro Masaoka거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제3호Pyloric Dysfunction: A Review of the Mechanisms, Diagnosis, and TreatmentEsquivel Micaela M., Gottfried-Blackmore Andres, Hwang Joo Ha, Joseph Abel A., Li Andrew A., Na Hee Kyong, Nguyen Linda, Podboy Alexander J.거트앤리버 소화기연관학회협의회 · Gut and Liver2025 · 제19권 제3호Technical review of gastric per-oral endoscopic myotomyAlexander Podboy, Joo Ha Hwang소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2019 · 제8권 제3호Post-surgical gastroparesis and beyond: The expanding role of G-POEM in foregut surgery complications and obesity careAlexander Joseph Podboy, Christopher Farid, Joselyne Tessa Tonleu소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2025 · 제14권 제4호Gastric per-oral endoscopic myotomy: Indications, technique, outcomes, and future directionsAmol Bapaye, Nachiket A. Dubale소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2020 · 제9권 제2호

이 간행물의 다른 논문 (18건)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-EfficiencyKim Gwang Ha, Lee Moon Wonpp. 807-808How to Optimize the Care Cascade of Hepatitis C Virus InfectionKim Beom Kyungpp. 809-810Forthcoming Step in Gastric Cancer Prevention: How Can Risk Stratification Be Combined with Endoscopic Screening for Gastric Cancer?Hamashima Chisatopp. 811-824Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel DiseaseChen Yang-Yuan, Hsiao Shun-Wen, Yen Hsu-Hengpp. 840-848Prolonged QT Interval in Cirrhosis: Twisting Time?Lee William, Vandenberk Bert, Raj Satish R., Lee Samuel S.pp. 849-860
원문 보기